Adaptimmune Therapeutics PLC (ADAPY) stock
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics PLC saw revenue fall 54.0% to $65.09M over the twelve months to Jun 30, 2025. Free cash flow was -$191.67M. At the latest close the market valued the company at $55.46M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2025
Valuation
- Market cap
- $55.46M
- P/E ratio
- –
- Price to sales
- 0.85
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -345.61%
Fundamentals
- Revenue
- $65.09M
- Net income
- -$169.76M
- EPS, diluted
- -$0.11
- Free cash flow
- -$191.67M
- Book value per share
- -$0.04
- Diluted shares
- 1.58B
Trading
- Previous close
- $0.03
- Open
- $0.02
- Day's range
- $0.02 – $0.04
- Volume
- 58,744
- Average volume (20 days)
- 229,354
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | ADAPY | S&P 500 | Difference | ADAPY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +55.6% | +0.6% | +54.9 pts | ||
| 3 months | -11.4% | +3.4% | −14.8 pts | ||
| Year to date | +34.6% | +13.3% | +21.3 pts | ||
| 1 year | -82.5% | +16.6% | −99.1 pts | ||
| 3 years | -94.0% | +86.4% | −180.3 pts | -60.8% | +23.1% |
| 5 years | -99.3% | +81.9% | −181.2 pts | -63.3% | +12.7% |
| 10 years | -99.3% | +318.9% | −418.2 pts | -39.4% | +15.4% |
Eleven years at a glance
Fiscal years 2013 to 2024 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Adaptimmune Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Results
- Results
- News
About Adaptimmune Therapeutics
Biological Products, (No Diagnostic Substances)
Adaptimmune is a commercial-stage biopharmaceutical company that develops and commercializes engineered T-cell immunotherapies to treat solid tumor cancers. The company utilizes autologous T-cell receptor and TRuC technology platforms to create personalized therapies from patients' own white blood cells. Its primary commercial product is TECELRA, an engineered T-cell therapy approved in the United States for adults with advanced or metastatic synovial sarcoma carrying specific genetic biomarkers. The company is also developing clinical and preclinical cell therapy candidates, including lete-cel for synovial sarcoma and liposarcoma, and uza-cel for head and neck cancer. Its therapies serve cancer patients with specific solid tumors, administered through specialized healthcare providers at medical centers.
Company profile, executives and historyAdaptimmune Therapeutics stock: common questions
What is Adaptimmune Therapeutics's stock price?
ADAPY closed at $0.04 on Oct 19, 2026, up 9.38% on the day.
What is Adaptimmune Therapeutics's market cap?
Adaptimmune Therapeutics was worth $55.46M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is ADAPY's P/E ratio?
Adaptimmune Therapeutics lost money over the twelve months to Jun 30, 2025 (diluted EPS -$0.11), so it has no meaningful P/E ratio.
How much revenue does Adaptimmune Therapeutics make?
Adaptimmune Therapeutics reported revenue of $65.09M for the twelve months to Jun 30, 2025, down 54.0% from a year earlier.
Does Adaptimmune Therapeutics pay a dividend?
No. Adaptimmune Therapeutics has not paid a cash dividend over the last twelve months.
How has ADAPY stock performed over the past year?
Including dividends, ADAPY returned -82.5% over the past year, against +16.6% for the S&P 500.
Who are Adaptimmune Therapeutics's competitors?
Companies most similar to Adaptimmune Therapeutics by business, industry and size include AUTL, CHRS, IOVA, STRO, IPSC.
See a number that looks wrong?